Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

22.26 -0.56 (-2.45%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

33 34 Next >

Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy ↗

July 25, 2025

Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients.

Via Benzinga

Sarepta Stock Slumps After EU Regulator Recommends Refusing Approval To Its Contentious Gene Therapy: Retail Expects Stock Bounceback ↗

July 25, 2025

Roche announced on Friday that it plans to continue working with the EMA to explore a potential path forward.

Via Stocktwits

Topics Death

Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe ↗

July 25, 2025

Shares are down another double-digit percentage after bad news continued piling on for gene therapy Elevidys.

Via Investor's Business Daily

Topics Death

Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT

July 25, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The Announcement ↗

July 23, 2025

Via Stocktwits

Sarepta Pauses Shipments Of DMD Drug Elevidys Amid FDA Label Review, Stock Tumbles After-Hours ↗

July 21, 2025

Via Stocktwits

Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT

July 25, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Intel, Absci, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

July 25, 2025

Via Benzinga

Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union

July 25, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Friday's pre-market session: top gainers and losers ↗

July 25, 2025

Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 25, 2025

Via Benzinga

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm

July 24, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent' For Gene Therapies. ↗

July 24, 2025

Sarepta stock is now trading at a nine-year low as the debacle with its gene therapy, Elevidys, continues.

Via Investor's Business Daily

Topics Death Workforce

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

July 24, 2025

Via Benzinga

Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT

July 24, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT

July 24, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗

July 24, 2025

Via Benzinga

Is This Stock a Buy After Soaring by 20% in 1 Day? ↗

July 24, 2025

Via The Motley Fool

Topics Death

Elevidys Halt Sparks Analyst Downgrades—Sarepta Races To Revise Label ↗

July 23, 2025

Analysts downgraded Sarepta as FDA pause on Elevidys raises regulatory uncertainty, leading to significant stock pressure and valuation cuts.

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT

July 23, 2025

From Pomerantz LLP

Via GlobeNewswire

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc. (SRPT) Shareholders

July 23, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc. (SRPT) Shareholders

July 23, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

FDA Names Biotech Veteran George Tidmarsh To Lead Drug Evaluation Division ↗

July 22, 2025

George Tidmarsh appointed to lead FDA drug review division amid staffing cuts and scrutiny over accelerated approvals and drug advertising rules.

Via Benzinga

Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT

July 22, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT

July 22, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

Sarepta Tumbles On The 'Painful' Decision To Stop Selling Elevidys ↗

July 22, 2025

Sarepta stock toppled Tuesday after the company said it would voluntarily stop all shipments of Elevidys.

Via Investor's Business Daily

Topics Death ETFs

Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review ↗

July 22, 2025

Sarepta pauses U.S. Elevidys shipments to complete FDA-requested safety label updates, aiming to resume distribution in the fourth quarter.

Via Benzinga

Agilysys Posts Downbeat Earnings, Joins NXP Semiconductors And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

July 22, 2025

Via Benzinga

This Lululemon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

July 22, 2025

Via Benzinga

Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.

July 21, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

33 34 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

All News about Sarepta Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today